Skip to main content
Clinical Trials/JPRN-UMIN000052877
JPRN-UMIN000052877
Not yet recruiting
未知

The effectiveness of patient reported outcome (PRO) in palliative care units : a cluster randomized controlled trial - The effectiveness of patient reported outcome (PRO) in palliative care units : a cluster randomized controlled trial

Tohoku University Graduate School of Medicine0 sites400 target enrollmentJanuary 24, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Cancer patients admitted to the Palliative Care Unit
Sponsor
Tohoku University Graduate School of Medicine
Enrollment
400
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 24, 2024
End Date
July 30, 2024
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Tohoku University Graduate School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients with obvious disturbance of consciousness. 2\. Patients who the physician or nurse practitioner determines are not appropriate for the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution - DuoTrav APS versus XALACOM® in Patient Reported Outcomes and Ocular Surface Health
EUCTR2009-010604-29-BEAlcon Research, Ltd.400
Completed
Phase 3
An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution.raised intra-ocular pressure with optic nerve damageraised intra-ocular pressure without optic nerve damage10018307
NL-OMON35130Alcon Laboratories30
Active, not recruiting
Not Applicable
An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using Travoprost APS Eye Drops Solution Versus XALATAN Eye Drops Solution - Travoprost APS versus XALATAN in OSDIOpen Angle Glaucoma or Ocular HypertensionMedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10030348Term: Open angle glaucoma
EUCTR2009-010606-10-GBAlcon Research, Ltd.516
Active, not recruiting
Not Applicable
An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution - DuoTrav APS versus XALACOM® in Patient Reported Outcomes and Ocular Surface Healthglaucoma/dry eyeMedDRA version: 9.1Level: LLTClassification code 10030348Term: Open angle glaucomaMedDRA version: 9.1Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10013774Term: Dry eye
EUCTR2009-010604-29-PTAlcon Research, Ltd.400
Active, not recruiting
Not Applicable
An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using Travoprost APS Eye Drops Solution Versus XALATAN Eye Drops Solution - Travoprost APS versus XALATAN® in Patient Reported Outcomes and Ocular Surface Health
EUCTR2009-010606-10-LTAlcon Research, Ltd.516